Key insights
- Eli Lilly and Novo Nordisk shares declined after CVS Health opted out of Medicare obesity drug coverage. This decision raises concerns about market access and reimbursement for these drugs, potentially impacting future revenue and profitability for LLY and NVO in the US market. The negative reaction reflects investor apprehension regarding the pace of adoption and coverage for new weight loss treatments.
Investing.com -- Shares of weight loss drug makers Eli Lilly and Novo Nordisk traded lower on Tuesday after CVS Health announced its decision regarding Medicare obesity drug coverage.
According to a company spokesperson quoted by Bloomberg News, ’CVS Health opted out of the Medicare obesity drug coverage model."
Eli Lilly shares fell 3.8%, while Novo Nordisk declined over 4.3% around 11 a.m.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.